Spondyloarthropathies
Özet
This chapter provides a comprehensive overview of spondyloarthritis (SpA), a chronic inflammatory rheumatological condition presenting with diverse phenotypic manifestations affecting both axial and peripheral joints, as well as associated extra-articular symptoms like inflammatory bowel disease, psoriasis, and acute anterior uveitis. The chapter specifically highlights the prevalence of cardiovascular disease (CVD) risk factors among SpA patients, noting significant associations with hypertension, smoking, and hyperlipidemia, which contribute to elevated morbidity and mortality rates. It underscores the necessity for vigilant cardiovascular risk management in this population, given the evidence indicating increased CVD risks compared to the general population. Insights from the ASAS-COMOSPA initiative and various studies are discussed, illustrating the complex interplay between traditional risk factors and inflammatory processes in SpA.
Bu bölüm, hem aksiyal hem de periferik eklemleri etkileyen çeşitli fenotipik belirtilerin yanı sıra inflamatuar bağırsak hastalığı, sedef hastalığı ve akut anterior üveit gibi eklem dışı semptomlarla ortaya çıkan kronik inflamatuar romatolojik bir durum olan spondiloartrit (SpA) hakkında kapsamlı bir genel bakış sunmaktadır. Bu bölüm özellikle SpA hastaları arasında kardiyovasküler hastalık (KVH) risk faktörlerinin yaygınlığını vurgulamakta, yüksek morbidite ve mortalite oranlarına katkıda bulunan hipertansiyon, sigara kullanımı ve hiperlipidemi ile önemli ilişkilere dikkat çekmektedir. Genel popülasyona kıyasla KVH risklerinin arttığını gösteren kanıtlar göz önüne alındığında, bu popülasyonda dikkatli kardiyovasküler risk yönetimi gerekliliğinin altını çizmektedir. ASAS-COMOSPA girişiminden ve çeşitli çalışmalardan elde edilen bilgiler, SpA'daki geleneksel risk faktörleri ve enflamatuar süreçler arasındaki karmaşık etkileşimi göstermektedir.
Referanslar
Rudwaleit M, van der Heijde D, Landewé R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection [published correction appears in Ann Rheum Dis. 2019 Jun;78(6):e59]. Ann Rheum Dis. 2009;68(6):777-783.
Rudwaleit M, van der Heijde D, Landewé R, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70(1):25-31.
van der Horst-Bruinsma IE, Nurmohamed MT. Management and evaluation of extra-articular manifestations in spondyloarthritis. Ther Adv Musculoskelet Dis. 2012;4(6):413-422.
Cigolini C, Fattorini F, Gentileschi S, Terenzi R, Carli L. Psoriatic arthritis: one year in review 2022. Clin Exp Rheumatol. 2022;40(9):1611-1619.
Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. Lancet. 2018;391(10136):2273-2284.
Liew JW, Ramiro S, Gensler LS. Cardiovascular morbidity and mortality in ankylosing spondylitis and psoriatic arthritis. Best Pract Res Clin Rheumatol. 2018;32(3):369-389.
Peters MJ, van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT. Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum. 2004;34(3):585-592.
Kavadichanda C, Shanoj KC, Ganapathy S, et al. Factors associated with high cardiovascular risk in psoriatic arthritis and non-psoriatic spondyloarthritis. Rheumatol Int. 2022;42(2):251-260.
Cardelli C, Monti S, Terenzi R, Carli L. One year in review 2021: axial spondyloarthritis. Clin Exp Rheumatol. 2021;39(6):1272-1281.
López-Medina C, Jiménez-Gómez Y, Moltó A, et al. Cardiovascular risk factors in patients with spondyloarthritis from Northern European and Mediterranean countries: An ancillary study of the ASAS-COMOSPA project. Joint Bone Spine. 2018;85(4):447-453.
Moltó A, Etcheto A, van der Heijde D, et al. Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study. Ann Rheum Dis. 2016;75(6):1016-1023.
Kim JH, Choi IA. Cardiovascular morbidity and mortality in patients with spondyloarthritis: A meta-analysis. Int J Rheum Dis. 2021;24(4):477-486.
Ben Tekaya A, Boukriba S, Fendri A, et al. Endothelial dysfunction and increased carotid intima-media thickness in patients with spondyloarthritis without traditional cardiovascular risk factors. RMD Open. 2022;8(2):e002270.
Ferraz-Amaro I, Rueda-Gotor J, Genre F, et al. Potential relation of cardiovascular risk factors to disease activity in patients with axial spondyloarthritis. Ther Adv Musculoskelet Dis. 2021;13:1759720X211033755.
Navarini L, Currado D, Marino A, et al. Persistence of C-reactive protein increased levels and high disease activity are predictors of cardiovascular disease in patients with axial spondyloarthritis. Sci Rep. 2022;12(1):7498.
Peters MJ, van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT. Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum. 2004;34(3):585-592.
Bhattad PB, Kulkarni M, Patel PD, Roumia M. Cardiovascular Morbidity in Ankylosing Spondylitis: A Focus on Inflammatory Cardiac Disease. Cureus. 2022;14(6):e25633.
Bengtsson K, Klingberg E, Deminger A, et al. Cardiac conduction disturbances in patients with ankylosing spondylitis: results from a 5-year follow-up cohort study. RMD Open. 2019;5(2):e001053.
Romand X, Adeline F, Dalecky M, et al. Systematic assessment of heart valves and cardiac function by echocardiography in axial spondyloarthritis: A systematic review and meta-analysis. Joint Bone Spine. 2022;89(4):105375.
Chou CH, Lin MC, Peng CL, et al. A nationwide population-based retrospective cohort study: increased risk of acute coronary syndrome in patients with ankylosing spondylitis. Scand J Rheumatol. 2014;43(2):132-136.
Feng KM, Chien WC, Chen YH, et al. Increased Risk of Acute Coronary Syndrome in Ankylosing Spondylitis Patients With Uveitis: A Population-Based Cohort Study. Front Immunol. 2022;13:890543.
González Mazón I, Rueda-Gotor J, Ferraz-Amaro I, et al. Subclinical atherosclerotic disease in ankylosing spondylitis and non-radiographic axial spondyloarthritis. A multicenter study on 806 patients. Semin Arthritis Rheum. 2021;51(2):395-403.
Rueda-Gotor J, Ferraz-Amaro I, Genre F, et al. Factors associated with atherosclerosis in radiographic and non-radiographic axial spondyloarthritis. A multicenter study on 838 patients. Semin Arthritis Rheum. 2022;55:152037.
Arévalo M, López-Medina C, Moreno Martinez-Losa M, et al. Role of HLA-B27 in the comorbidities observed in Axial Spondyloarthritis: Data from COMOSPA. Joint Bone Spine. 2020;87(5):445-448.
Lai Y, Zhang Y, Mo S, et al. Prevalence of comorbidities and risk factors in spondyloarthritis: results of a cross-sectional study. Ann Rheum Dis. 2022;81(3):e43.
Lehtinen K. Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis. Ann Rheum Dis. 1993;52(3):174-176.
Ahlehoff O, Gislason GH, Charlot M, et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med. 2011;270(2):147-157.
Horreau C, Pouplard C, Brenaut E, et al. Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. J Eur Acad Dermatol Venereol. 2013;27 Suppl 3:12-29.
Ogdie A, Maliha S, Shin D, et al. Cause-specific mortality in patients with psoriatic arthritis and rheumatoid arthritis. Rheumatology (Oxford). 2017;56(6):907-911.
Juneblad K, Rantapää-Dahlqvist S, Alenius GM. Disease Activity and Increased Risk of Cardiovascular Death among Patients with Psoriatic Arthritis. J Rheumatol. 2016;43(12):2155-2161.
Jamnitski A, Symmons D, Peters MJ, Sattar N, McInnes I, Nurmohamed MT. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review [published correction appears in Ann Rheum Dis. 2013 Mar;72(3):467. McIinnes, Iain [corrected to McInnes, Iain]]. Ann Rheum Dis. 2013;72(2):211-216.
Polachek A, Touma Z, Anderson M, Eder L. Risk of Cardiovascular Morbidity in Patients With Psoriatic Arthritis: A Meta-Analysis of Observational Studies [published correction appears in Arthritis Care Res (Hoboken). 2019 Apr;71(4):574]. Arthritis Care Res (Hoboken). 2017;69(1):67-74.
Gladman DD, Ang M, Su L, Tom BD, Schentag CT, Farewell VT. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis. 2009;68(7):1131-1135.
Lauper K, Courvoisier DS, Chevallier P, Finckh A, Gabay C. Incidence and Prevalence of Major Adverse Cardiovascular Events in Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis. Arthritis Care Res (Hoboken). 2018;70(12):1756-1763.
Cooksey R, Brophy S, Kennedy J, et al. Cardiovascular risk factors predicting cardiac events are different in patients with rheumatoid arthritis, psoriatic arthritis, and psoriasis. Semin Arthritis Rheum. 2018;48(3):367-373.
Bengtsson K, Forsblad-d'Elia H, Lie E, et al. Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study. Arthritis Res Ther. 2017;19(1):102.
Jafri K, Bartels CM, Shin D, Gelfand JM, Ogdie A. Incidence and Management of Cardiovascular Risk Factors in Psoriatic Arthritis and Rheumatoid Arthritis: A Population-Based Study. Arthritis Care Res (Hoboken). 2017;69(1):51-57.
Radner H, Lesperance T, Accortt NA, Solomon DH. Incidence and Prevalence of Cardiovascular Risk Factors Among Patients With Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis. Arthritis Care Res (Hoboken). 2017;69(10):1510-1518.
Dubreuil M, Rho YH, Man A, et al. Diabetes incidence in psoriatic arthritis, psoriasis and rheumatoid arthritis: a UK population-based cohort study. Rheumatology (Oxford). 2014;53(2):346-352.
Kimhi O, Caspi D, Bornstein NM, et al. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum. 2007;36(4):203-209.
Khraishi M, Aslanov R, Rampakakis E, Pollock C, Sampalis JS. Prevalence of cardiovascular risk factors in patients with psoriatic arthritis. Clin Rheumatol. 2014;33(10):1495-1500.
Eder L, Abji F, Rosen CF, Chandran V, Gladman DD. The Association Between Obesity and Clinical Features of Psoriatic Arthritis: A Case-control Study. J Rheumatol. 2017;44(4):437-443.
Costa L, Caso F, Ramonda R, et al. Metabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: an observational study. Immunol Res. 2015;61(1-2):147-153.
Mok CC, Ko GT, Ho LY, Yu KL, Chan PT, To CH. Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. Arthritis Care Res (Hoboken). 2011;63(2):195-202.
Nurmohamed MT, van der Horst-Bruinsma I, Maksymowych WP. Cardiovascular and cerebrovascular diseases in ankylosing spondylitis: current insights. Curr Rheumatol Rep. 2012;14(5):415-421.
Ramonda R, Lo Nigro A, Modesti V, et al. Atherosclerosis in psoriatic arthritis. Autoimmun Rev. 2011;10(12):773-778.
Bodur H. Cardiovascular comorbidities in spondyloarthritis [published online ahead of print, 2022 Dec 13]. Clin Rheumatol. 2022;10.1007/s10067-022-06473-9.
Poddubnyy D, Sieper J. Treatment of Axial Spondyloarthritis: What Does the Future Hold?. Curr Rheumatol Rep. 2020;22(9):47.
Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011;342:c7086.
Coxib and traditional NSAID Trialists' (CNT) Collaboration, Bhala N, Emberson J, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769-779.
Tsai WC, Ou TT, Yen JH, Wu CC, Tung YC. Long-term frequent use of non-steroidal anti-inflammatory drugs might protect patients with ankylosing spondylitis from cardiovascular diseases: a nationwide case-control study. PLoS One. 2015;10(5):e0126347.
Wu LC, Leong PY, Yeo KJ, et al. Celecoxib and sulfasalazine had negative association with coronary artery diseases in patients with ankylosing spondylitis: A nation-wide, population-based case-control study. Medicine (Baltimore). 2016;95(36):e4792.
Dubreuil M, Louie-Gao Q, Peloquin CE, Choi HK, Zhang Y, Neogi T. Risk of myocardial infarction with use of selected non-steroidal anti-inflammatory drugs in patients with spondyloarthritis and osteoarthritis. Ann Rheum Dis. 2018;77(8):1137-1142.
Roubille C, Richer V, Starnino T, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74(3):480-489.
Spanakis E, Sidiropoulos P, Papadakis J, et al. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. J Rheumatol. 2006;33(12):2440-2446.
Atzeni F, Nucera V, Galloway J, Zoltán S, Nurmohamed M. Cardiovascular risk in ankylosing spondylitis and the effect of anti-TNF drugs: a narrative review. Expert Opin Biol Ther. 2020;20(5):517-524.
Ibáñez Vodnizza SE, Nurmohamed MT, Visman IM, et al. Fat Mass Lowers the Response to Tumor Necrosis Factor-α Blockers in Patients with Ankylosing Spondylitis. J Rheumatol. 2017;44(9):1355-1361.
Gwinnutt JM, Wieczorek M, Cavalli G, et al. Effects of physical exercise and body weight on disease-specific outcomes of people with rheumatic and musculoskeletal diseases (RMDs): systematic reviews and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs. RMD Open. 2022;8(1):e002168.
Michelsen B, Berget KT, Kavanaugh A, Haugeberg G. Association between TNFi anti-drug antibodies, smoking, and disease activity in patients with inflammatory arthritis: Results from a Norwegian cross-sectional observational study. Rheumatol Ther. 2022;9(4):1171-1179.
Toussirot E. The Risk of Cardiovascular Diseases in Axial Spondyloarthritis. Current Insights. Front Med (Lausanne). 2021;8:782150.
Merola JF, McInnes IB, Deodhar AA, et al. Effect of Secukinumab on Traditional Cardiovascular Risk Factors and Inflammatory Biomarkers: Post Hoc Analyses of Pooled Data Across Three Indications. Rheumatol Ther. 2022;9(3):935-955.
Poddubnyy D, Sieper J. Treatment of Axial Spondyloarthritis: What Does the Future Hold?. Curr Rheumatol Rep. 2020;22(9):47.
Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022;386(4):316-326.
Castañeda S, Vicente-Rabaneda EF, García-Castañeda N, Prieto-Peña D, Dessein PH, González-Gay MA. Unmet needs in the management of cardiovascular risk in inflammatory joint diseases. Expert Rev Clin Immunol. 2020;16(1):23-36.
Yagensky V, Schirmer M. Cardiovascular Risks and Risk Stratification in Inflammatory Joint Diseases: A Cross-Sectional Study. Front Med (Lausanne). 2022;9:786776.
